Search Results
Apr 16, 2026, 03:07 ET BIO Asia-Taiwan 2026 to Be Held in Mid-July in Taipei
companies such as Alar Pharmaceuticals and Pharmosa Biopharm have secured licensing deals worth hundreds of millions of US dollars. A recently approved gene therapy for AADC deficiency developed by NTU Hospital, serves as a model for translating academic research into commercialized therapies. Additionally,
More news about: Taiwan Bio Industry Organization
Apr 15, 2026, 15:26 ET Seragon Publishes Data for Longevity Drug SRN-901 Showing Significant Lifespan and Healthspan Extension
placebo-treated mice. Transcriptomic Modulation of Aging Pathways: Transcriptomic analyses revealed that SRN-901 modulates gene expression across pathways implicated in aging biology. Pathways related to DNA repair were upregulated in the SRN-901 treated mice. Conversely, pathways
More news about: Seragon Biosciences
Apr 15, 2026, 13:33 ET TEDCO's Maryland Innovation Initiative Announces More Than $2.1M to Latest Awardees
aquatic biological samples; Johns Hopkins University; received $300,000Aletira Therapeutics, Inc. - Next generation gene therapy to prevent the most common form of hereditary hearing loss; Johns Hopkins University; received $300,000The Technology Assessment
More news about: TEDCO
Apr 15, 2026, 12:05 ET Alida Biosciences Launches EpiPlex® Tri-Mod™ Service for Simultaneous Profiling of Three Key mRNA Modifications
modifications from RNA-limited clinical samples through an end-to-end workflow, including EpiScout™ analysis software. By combining modification detection with gene expression, EpiPlex provides a multidimensional view of RNA regulation that extends beyond traditional sequencing approaches.Solving an Unsolved
More news about: Alida Biosciences
Apr 15, 2026, 11:43 ET Downstream Processing Market Trends, Size Surges to USD 20.3 Billion by 2033, Propelled by 6.8% CAGR - Verified Market Reports®
high-stakes expansion phase driven by surging biopharmaceutical production, intensified demand for monoclonal antibodies, and rapid scale-up of cell and gene therapies. Market dynamics reveal strong momentum across purification technologies, chromatography resins, and filtration systems as manufacturers pursue
More news about: Verified Market Reports
Apr 15, 2026, 10:01 ET Gene Expression Analysis Market worth $5.93 billion by 2031 | MarketsandMarkets™
Gene Expression Analysis Market Trends & Insights:By application, the drug discovery & development segment accounted for the largest share of the gene expression analysis market in 2025. This is attributed to the extensive use of gene expression profiling
More news about: MarketsandMarkets
Apr 15, 2026, 10:00 ET Axtria Acquires Conexus Solutions, Uniting Agentic AI and CRM Mastery to Redefine Life Sciences Commercialization
commercial, quality and R&D operations are undergoing a structural transformation. Patent cliffs are compressing revenue timelines. Specialty and cell-and-gene therapies demand hyper-targeted engagement across smaller, harder-to-reach populations. Payers are raising the bar on outcomes-based evidence. And at
More news about: Axtria, Inc.
Apr 15, 2026, 10:00 ET Axtria Acquires Conexus Solutions, Uniting Agentic AI and CRM Mastery to Redefine Life Sciences Commercialization
commercial, quality and R&D operations are undergoing a structural transformation. Patent cliffs are compressing revenue timelines. Specialty and cell-and-gene therapies demand hyper-targeted engagement across smaller, harder-to-reach populations. Payers are raising the bar on outcomes-based evidence. And at
More news about: Axtria, Inc.
Apr 15, 2026, 09:43 ET Tsingke Unveils 'Zero-Contact' Gene Synthesis to Safeguard Core Genetic Sequences
biotech R&D evolve, ensuring gene synthesis security and protecting intellectual property are more critical than ever. The Zero-Contact system represents more than a step forward in sequence security—it reflects our forward-looking approach to the future of gene research. Through innovations like
More news about: Beijing Tsingke Biotech Co., Ltd.
Apr 15, 2026, 09:43 ET Tsingke Unveils 'Zero-Contact' Gene Synthesis to Safeguard Core Genetic Sequences
biotech R&D evolve, ensuring gene synthesis security and protecting intellectual property are more critical than ever. The Zero-Contact system represents more than a step forward in sequence security—it reflects our forward-looking approach to the future of gene research. Through innovations like
More news about: Beijing Tsingke Biotech Co., Ltd.
Apr 15, 2026, 08:00 ET Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
experience spanning pharmaceutical R&D, biotechnology, and early clinical development. She currently holds a professorial appointment and leads the Gene Regulation and Translational Medicine Laboratory at QIMR Berghofer Medical Research Institute and previously held senior scientific roles at Sanofi/Rhône-Poulenc
More news about: Kazia Therapeutics Limited
Apr 14, 2026, 17:45 ET Partner Therapeutics announces submission of supplemental Biologics License Application (sBLA) to FDA for BIZENGRI® (zenocutuzumab-zbco) in NRG1 Fusion Positive Cholangiocarcinoma and Inclusion in updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
harboring a neuregulin 1 (NRG1) gene fusion. Cholangiocarcinoma is a rare, aggressive malignancy of the bile ducts with few effective treatment options. There are no approved therapies specifically targeting cholangiocarcinoma harboring NRG1 gene fusions.
More news about: Partner Therapeutics, Inc.
Apr 14, 2026, 14:00 ET RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit
defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. Defendants' statements included, among other things,
More news about: THE ROSEN LAW FIRM, P. A.
Apr 14, 2026, 13:57 ET Global CMO/CDMO Market Set for Steady Growth as Biologics Outsourcing and Specialized Manufacturing Drive Demand | Future Market Insights (FMI)
commercial-scale production. Key drivers include:Tight in-house biomanufacturing capacityRising complexity of biologics, gene therapies, and personalized medicinesNeed for rapid scale-up and tech transfer capabilitiesPreference for modular and flexible manufacturing
More news about: Future Market Insights
Apr 14, 2026, 10:00 ET UPSHER-SMITH LAUNCHES NEW ONLINE RESOURCES TO SUPPORT THE DUCHENNE COMMUNITY
Dystrophy Duchenne muscular dystrophy (DMD) is a rare genetic condition that causes progressive muscle weakness due to a change in the gene that encodes for dystrophin, a protein needed for normal muscle function. It impacts around 15,000 individuals in the United States, and over 300,000
More news about: Upsher-Smith Laboratories, LLC
Apr 14, 2026, 09:30 ET Lung Cancer Research Foundation Grants Team Science Award Focused on Curing EGFR-Mutant Lung Cancers
of cancer death worldwide. A common subtype, lung adenocarcinoma (LUAD), frequently carries mutations in the epidermal growth factor receptor (EGFR) gene occurring in about 10% of lung cancers in people of European or African ancestry and up to 45% in those of East Asian ancestry. Oral drugs called tyrosine
More news about: Lung Cancer Research Foundation
Apr 14, 2026, 09:00 ET RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit -- The Gross Law Firm
defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. Defendants' statements included, among other things,
More news about: The Gross Law Firm
Apr 14, 2026, 08:36 ET Corteva Announces Executive Leadership Team of its Future Advanced Seed and Genetics Company
agriculture industry's most elite germplasm and transformative biotech. The company will leverage its next generation scientific expertise in disciplines like gene editing and molecular breeding to further strengthen its core business while exploring opportunities to expand to new row crops – and potentially beyond.
More news about: Corteva, Inc.
Apr 14, 2026, 08:00 ET Andelyn Biosciences Partners with Evolyra Therapeutics for the Clinical Manufacturing of Gene Therapies for the Treatment of Limb-Girdle Muscular Dystrophies
/PRNewswire/ -- Andelyn Biosciences, a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), announced today a partnership with Evolyra Therapeutics to manufacture clinical-grade AAV gene therapies for treating types 2C and 2D Limb-Girdle Muscular Dystrophies
More news about: Andelyn Biosciences
Apr 14, 2026, 07:05 ET Ledger Run First to Bring AI-Powered Automation to Clinical Trial Payments
disproportionate site-to-trial ratio is growing, especially with the increased need for specialty sites that have experience in novel sciences such as cell and gene therapy and radiopharmaceuticals. Experienced sites are in high demand, and a positive payment experience can determine whether a sponsor becomes a
More news about: Ledger Run
Apr 14, 2026, 07:00 ET Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide
Statistically significant reduction in Srebf1, a key gene driving fat production in the liverIncreased expression of Pparα, a central regulator of fat metabolism and fat burningGDNF outperformed semaglutide in key gene expression markers tied to liver fat regulationDemonstrated
More news about: Hoth Therapeutics, Inc.
Apr 14, 2026, 07:00 ET Cardinal Health report highlights growing momentum to expand advanced therapies into community care settings
Expansion, offering new insights into how the expanding advanced therapy pipeline is reshaping sites of care. Advanced therapies are innovative gene-, cell- and tissue-based treatments that target the root cause of disease by repairing, replacing or regenerating damaged cells, offering long-term benefits
More news about: Cardinal Health
Apr 14, 2026, 05:50 ET Green Surfactants And Emulsifiers Market Set to Reach USD 2.73 Bn by 2035 as Sustainable Chemistry and Bio-Based Innovations Accelerate Global Industry Transformation: - Market Research Intellect
II (Biologics and Monoclonal Antibodies), Type III (Cell and Gene Therapies), Type IV (Vaccines and Immune Modulators), Type V (RNA‑Based Therapeutics)), By Application (Oncology Treatment Channels, Rare Disease Therapeutics, Cell and Gene Therapy Platforms, Respiratory and Immunology Applications, Neuromuscular
More news about: Market Research Intellect
Apr 14, 2026, 03:00 ET ARTHEx Biotech Announces Participation at the 25th Annual Needham Virtual Healthcare Conference
conference.About ARTHEx BiotechARTHEx Biotech is a clinical-stage company developing targeted RNA medicines designed to precisely modulate gene expression. Its proprietary platform, BOOST-ONÔ, pairs selective oligonucleotides with enhanced tissue delivery to reach skeletal muscle, heart, and
More news about: ARTHEx Biotech
Apr 14, 2026, 02:37 ET triSure NIPT首次在台灣正式發表: 將非侵入性產前篩檢從染色體異常延伸至更全面的基因風險評估
風險評估新階段。Gene Solutions 致力於為台灣臨床醫師與孕產家庭提供最全面、非侵入性且具科學實證支持的篩檢工具，協助做出更精準且更具信心的孕期決策。https://genesolutions.com/our-test/trisure-procare 關於 Gene SolutionsGene Solutions 為總部位
More news about: Gene Solutions Genomics Pte., Ltd